Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
49 Cards in this Set
- Front
- Back
- 3rd side (hint)
Aminoglycosides
|
-Gentamicin
-Tobramycin -amikacin -streptomycin -neomycin |
mycins
|
|
Aminoglycosides MOA
|
Bacteriocidal
-Inhibition of bacterial protien synthysis by interacting withribosomal binding sites |
|
|
Aminoglycosides MOR
|
inactivation of drug by bacterial enzymes
-Failure of permeation of the drug across the cell membrane |
|
|
Aminoglycosides spectrum
|
-very good against gram negative
-synergy with beta lactam drugs |
|
|
Aminoglycosides pharmacokinetics
|
poor absorbtion IM, IV
-no BBB give IT for menegitis -peak 3-10 mcg/ml -trough <2mcg/ml |
|
|
Aminoglycosides AE
|
-Nephrotoxic
-ototoxic -neuromuscular blockade avoid myasthenia gravis |
|
|
Vancomycin
|
MOA bacteriocidal, cell wall synthisis
-gram pos MRSA, cdiff oral AE red man, ototoxic, nephrotoxic |
|
|
Aminoglycosides
Mechanism of Action |
Inhibition of protein synthesis
Irreversibly binds to ribosomes decreases overall protein synthesis, and produces misreading of mRNA |
|
|
AminoglycosidesSpectrum of Activity
|
-Gram-Negative Aerobes
Pseudomonas aeroginosa -Gram-Positive Aerobes Synergistic activity with beta-lactam antibiotics |
|
|
Aminoglycosides
Adverse Effects |
Nephrotoxicity
Ototoxicity |
|
|
AminoglycosidesMonitoring Serum Levels
|
Blood levels drawn at steady state
Peak levels should be drawn: 1 hr after the START of an IV infusion (30-45 minutes) 1 hr after an IM injection Trough levels just prior to infusion Random levels are drawn between 6-14 hours after first dose |
|
|
Aminoglycosides
Clinical Indications |
Gram negative
In combination with penicillin, ampicillin or vancomycin for Gram positive infections Neomycin orally/bowel decontamination |
|
|
Vancomycin
Mechanism of Action |
Inhibits bacterial cell wall synthesis at a site different than beta-lactams
Bactericidal (except for Enterococcus) |
cell wall
|
|
Vancomycin
Mechanism of Resistance |
Prolonged or indiscriminate use may lead to the emergence of resistant bacteria
Clinical resistance is extremely rare |
|
|
VancomycinSpectrum of Activity
|
Gram-positive bacteria
|
|
|
Vancomycin
Clinical Uses |
-methicillin-resistant staph, osteomyelitis
Serious gram-positive -lactam allergic patients Endocarditis or surgical prophylaxis -refractory C. difficile |
|
|
Vancomycin
Adverse Effects |
Red-Man Syndrome
|
|
|
Vancomycin
Adverse Effects |
Red-Man Syndrome
Nephrotoxicity and Ototoxicity - rash neutropenia, thrombocytopenia |
|
|
Macrolides
|
Erythromycin
Clarithromycin (Biaxin®) Azithromycin (Zithromax®) |
|
|
Macrolides
MOA |
Inhibits protein synthesis by reversibly binding to the 50S ribosomal subunit
Suppression of RNA-dependent protein synthesis |
|
|
Macrolide Spectrum of Activity
|
Gram-Positive Aerobes
(Clarithro>Erythro>Azithro) -Gram-Negative Aerobes Azithro>Clarithro>Erythro) |
|
|
MacrolidesClinical Indication
|
Strep infections in pennallergic patients
N. gonorrhea Legionella, Chlamydia, Mycoplasma spp., or Campylobacter jejuni Lyme disease: |
|
|
Macrolides
Adverse Effects |
-Gastrointestinal
-Cholestatic hepatitis -Thrombophlebitis -ototoxicity |
|
|
Macrolides
Drug Interactions |
Theophylline
Cyclosporine Warfarin Antiarrhythmics |
|
|
Ketolides
|
Telithromycin (KetekTM)
|
|
|
Ketolides
Mechanism of Action |
Similar to macrolides
Binds to bacterial ribosomes and inhibits protein synthesis |
|
|
Ketolides
Microbiologic Spectrum |
Strep Staph
influenzae Moraxella catarrhalis gonorrhea Legionella Chlamydia Mycoplasma pneumoniae: |
|
|
Ketolides
Pharmacokinetics |
Absorption:
Adequate but incomplete Penetrates well into most body fluids no CSF Hepatic metabolism and renal |
|
|
Ketolides
Clinical Indications |
Treatment of upper and lower respiratory tract infections
Treatment of Legionella, Chlamydia, or Mycoplasma spp. |
|
|
Ketolides
Adverse Effects |
GI: Visual disturbances
Acute liver failure Exacerbation of myasthenia gravis Black box warning |
|
|
Ketolides
Drug Interactions |
Theopylline
Cyclosporine Warfarin Class IA and III antiarrhythmics |
|
|
Tetracyclines Pharmacology
|
Inhibit bacterial protein synthesis
|
|
|
Tetracyclines
Spectrum of Activity |
gram positive and gram negative
gonorrhea Rocky mountain syphyllis, Lyme Chlamydia Mycoplasma lyme disease |
|
|
Tetracyclines Drug Interactions
|
Chelation with multivalent cations:
Mg, Al, Fe, Ca, Zn, Cr |
|
|
Tetracyclines Side Effects
|
Inhibit bone growth
Tooth discoloration Hepatotoxicity Fungal superinfection Photosensitivity Hypersensitivity reactions Nephrotoxicity |
|
|
Glycylcycline
|
Tigeycyline (Tygacil®)
|
|
|
Glycylcycline
Mechanism of Action |
Bacteriostatic
|
|
|
GlycylcyclineMicrobiologic Spectrum
|
Broad spectrum of activity
|
|
|
GlycylcyclineClinical Indications
|
Mutlidrug resistant organisms Intra-abdominal infections
|
|
|
GlycylcyclineDrug Interactions
|
Oral anticoagulants – increased risk of bleeding
|
|
|
GlycylcyclineAdverse Events
|
GI: Photosensitivity: “sunburn” Development of superinfection with candida
Anti-anabolic action |
|
|
ClindamycinMechanism of Action
|
Binds to bacterial ribosomes and inhibits protein synthesis
Bacteriostatic |
|
|
Clindamycin Spectrum of Activity
|
Gram-Positive Aerobes
|
|
|
ClindamycinPharmacokinetics
|
Well absorbed
Widely distributed except into the CSF Hepatic metabolism |
|
|
ClindamycinClinical Indications
|
Respiratory tract infections
Aspiration pneumonia Empyema Skin and soft tissue infections Intra-abdominal and pelvic infections |
|
|
MetronidazoleFlagyl®
Mechanism of Action |
inhibits DNA synthesis
bactericidal |
|
|
Metronidazole Spectrum of Activity
|
Anaerobic Bacteria (BDA)
Anaerobic Protozoa |
|
|
Metronidazole
Pharmacokinetics |
Well absorbed
Well distributed including the CSF and breast milk Hepatic metabolism |
|
|
Metronidazole
Adverse Effects |
Gastrointestinal
metallic taste CNS – most serious Disulfiram reaction with alcohol |
|